Coating member

The covering member integrates antibacterial and antiviral agents with a larger appearance modifier to achieve both properties and a matte appearance, addressing the challenge of simultaneous property integration in covering members.

JP2024159304APending Publication Date: 2024-11-08PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023075209
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing covering members struggle to simultaneously impart both antibacterial and antiviral properties while achieving a matte appearance.

Method used

A covering member comprising a base material and a film that includes a particulate antibacterial and antiviral agent and a particulate appearance adjusting agent with a specific particle size ratio, where the average particle size of the appearance modifier is 2.5 to 100 times larger than the antibacterial and antiviral agent, and the film thickness ratio is 1.1 to 4 times, ensuring both properties are effectively integrated.

Benefits of technology

The solution achieves a covering member with both antibacterial and antiviral properties and a matte appearance, with the antibacterial and antiviral agent particles stably retained near the surface, effectively expressing their actions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159304000001_ABST
    Figure 2024159304000001_ABST
Patent Text Reader

Abstract

To provide a coating member having a substrate and a coating film coating the substrate, to which antibacterial antiviral properties are given while a matte appearance is given.SOLUTION: A coating member 1 includes a substrate 2 and a coating film 3 coating the substrate 2. The coating film 3 includes: a granular antibacterial antiviral agent (A); and a granular appearance modifying agent (B) the average grain diameter of which is larger than that of the antibacterial antiviral agent (A). The ratio between the average grain diameter of the antibacterial antiviral agent (A) and the granular appearance modifying agent (B) ranges from 1:2.5 to 1:100. The ratio between the minimum thickness T2 of the coating film and the maximum thickness T1 of the coating film ranges from 1:1.1 to 1:4.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a coated member, and more particularly to a coated member including a substrate and a coating covering the substrate. [Background technology]

[0002] Patent Document 1 describes a coating composition including a polymer (a) having a polyorganosiloxane structure and a hydroxyl group, a polymer (b) not having a polyorganosiloxane structure, a curing agent (c) having a functional group capable of reacting with the hydroxyl group, an antibacterial and antiviral agent (d) having an average particle size of 0.1 μm to 5.0 μm, and a dispersant (e), and a coated product having a coating layer formed from the coating composition. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Patent Publication No. 2022-093225 Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present disclosure is to impart a matte appearance while also imparting antibacterial and antiviral properties to a coated member comprising a substrate and a coating covering the substrate. [Means for solving the problem]

[0005] A coated member according to one embodiment of the present disclosure includes a substrate and a coating that coats the substrate. The coating contains a particulate antibacterial and antiviral agent (A) and a particulate appearance-adjusting agent (B) having an average particle size larger than that of the antibacterial and antiviral agent (A). The ratio of the average particle size of the antibacterial and antiviral agent (A) to the average particle size of the appearance-adjusting agent (B) is 1:2.5 to 1:100. The ratio of the minimum thickness of the coating to the maximum thickness of the coating is 1:1.1 to 1:4. Effect of the Invention

[0006] According to one aspect of the present disclosure, a coated member comprising a substrate and a coating covering the substrate can be imparted with a matte appearance while also being imparted with antibacterial and antiviral properties. [Brief description of the drawings]

[0007] [Figure 1] FIG. 1 is a cross-sectional view of a covering member in an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] Hereinafter, an embodiment of the present disclosure will be described with reference to FIG. 1. The following embodiment is merely a part of various embodiments of the present disclosure. In addition, the following embodiment can be modified in various ways depending on the design, etc., as long as the object of the present disclosure can be achieved. The figures referred to below are schematic diagrams, and the dimensional ratios of the components in the figures do not necessarily reflect the actual dimensional ratios. The action mechanism of the embodiment shown below is estimated, and the present disclosure is not bound by the following explanation of the action mechanism.

[0009] A coated member 1 according to the embodiment includes a substrate 2 and a coating 3 that coats the substrate 2. The coating 3 contains a particulate antibacterial and antiviral agent (A) and a particulate appearance-adjusting agent (B) having a larger average particle size than the antibacterial and antiviral agent (A). The ratio of the average particle size of the antibacterial and antiviral agent (A) to the average particle size of the appearance-adjusting agent (B) is 1:2.5 to 1:100. The ratio of the minimum thickness T2 of the coating 3 to the maximum thickness T1 of the coating 3 is 1:1.1 to 1:4.

[0010] The antibacterial and antiviral agent (A) is a substance having antibacterial and antiviral properties. The antibacterial and antiviral properties refer to at least one of antibacterial and antiviral properties. The coating 3 may cover the entire surface of the substrate 2, or may cover only a part of the surface of the substrate 2.

[0011] The average particle size of the antibacterial and antiviral agent (A) is a cumulant analysis particle size calculated from a particle size distribution based on scattering intensity measured by dynamic light scattering. The average particle size of the antibacterial and antiviral agent (A) is the average particle size of the antibacterial and antiviral agent (A) in the composition (X) and in the coating 3. This average particle size is a value measured without subjecting the antibacterial and antiviral agent (A) to a crushing treatment, and therefore, when the particles 5 of the antibacterial and antiviral agent (A) are aggregated, it is the average secondary particle size, and when they are not aggregated, it is the average primary particle size.

[0012] The average particle size of the appearance-adjusting agent (B) is the 50% cumulative particle size (median size D50) calculated from the particle size distribution based on scattering intensity measured by a laser diffraction method. This average particle size is the primary particle size.

[0013] According to this embodiment, the coating 3 imparts a matte appearance, and the appearance is not easily marred even if the coating 3 contains the antibacterial and antiviral agent (A).

[0014] That is, since the coating 3 contains the antibacterial and antiviral agent (A), the coating 3 can impart antibacterial and antiviral properties to the coated member 1, and since the coating 3 contains the appearance-adjusting agent (B), the coating 3 can impart a matte appearance to the coated member 1. Furthermore, since the average particle size of the appearance-adjusting agent (B) is 2.5 to 100 times the average particle size of the antibacterial and antiviral agent (A) and the maximum thickness T1 of the coating 3 is 1.1 times or more the minimum thickness T2 of the coating 3, it is possible to satisfactorily impart both the antibacterial and antiviral properties by the antibacterial and antiviral agent (A) and the matte appearance by the appearance-adjusting agent (B).

[0015] It is difficult to impart a matte appearance to the coated member 1 while imparting good antibacterial and antiviral properties using only the particulate antibacterial and antiviral agent (A). Also, it is difficult to impart a matte appearance to the coated member 1 while imparting good antibacterial and antiviral properties by simply using the antibacterial and antiviral agent (A) in combination with the appearance modifier (B) without considering the thickness of the coating 3 and the relationship between the particle size of the antibacterial and antiviral agent (A) and the particle size of the appearance modifier (B). In the embodiment, by not only simply using the antibacterial and antiviral agent (A) in combination with the appearance modifier (B), but also specifying the relationship between the maximum thickness T1 and the minimum thickness T2 of the coating 3 and the relationship between the average particle size of the antibacterial and antiviral agent (A) and the average particle size of the appearance modifier (B) as described above, it is possible to impart a matte appearance to the coated member 1 while imparting good antibacterial and antiviral properties.

[0016] The covering member 1 can be preferably applied to, for example, a member that requires good design and is touched by human hands. For example, the base material 2 in the covering member 1 is preferably a wiring device such as a switch or a socket. More specifically, the coating 3 is formed so as to cover the outer surface of a decorative panel in a wiring device, such as the outer surface of a switch panel (also called a switch cover or switch plate) in a switch, or the outer surface of a socket panel (also called a socket cover or socket plate) in a socket.

[0017] The film 3 is made, for example, from a film-forming composition (hereinafter also referred to as composition (X)).

[0018] Composition (X) contains, for example, a particulate antimicrobial and antiviral agent (A), an appearance-adjusting agent (B) other than the antimicrobial and antiviral agent (A), and a binder component (C).

[0019] The antibacterial and antiviral agent (A) may include any substance having antibacterial and antiviral properties. For example, the antibacterial and antiviral agent (A) may be a metal salt such as crystalline sodium aluminosilicate, silver-substituted zeolite, silver-zinc zeolite, silver zeolite, zirconium phosphate-silver oxide, zirconium phosphate-silver oxide-zinc oxide, titanium phosphate, gel mixture of zinc oxide and titanium oxide, mixture of silver titanium phosphate-silver supported gel and zinc oxide, silver supported silicon dioxide, silver oxide, ammonium polyphosphate, sodium phosphate, silver chloride, silver, zinc oxide, copper compounds, metallic copper, tetraamine copper ion, phosphoric acid-glass, and hydrophilic amino silicone polymers containing metal oxides; piguanide, chlorhexidine gluconate, chlorhexidine gluconate-poloctoolamine, polyhexamethylene piguanide hydrochloride, chlorhexidine, 2-acrylonitrile, 2-aminopropyl phosphate ... Organic synthetic antibacterial agents such as arylamide-2-methylpropanesulfonic acid copolymers and combinations of polyhexamethylene piguanide hydrochloride and zinc oxide; carbanilides such as triclocarban, combinations of triclocarban and nalidixic acid, and phenylamide compounds; amphoteric surfactants such as alkylamidopropyl dimethyl β-hydroxyammonium salts·polyoxyethylene (dimethylamino) ethylene (dimethylimino) ethylene chloride; carboxylic acids such as polymethacrylic acid, combinations of polyacrylates and zinc sulfate, and nalidixan (1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; alcohols such as polyhydric alcohol compounds;Benzalkonium chloride, organic silicone quaternary ammonium salts, N-polyoxyalkylene-N,N,N-trialkylene ammonium salts, alkyldanion ammonium carboxylates, alkyldimethyl ammonium salts, alkyldimethyl benzalkonium salts, alkyl quaternary ammonium salts, N,N,N,N-tetraalkyl quaternary ammonium salts, cetyltrimethylammonium chloride, dialkyl quaternary ammonium salts, tetraalkyl quaternary ammonium salts, octadecyldimethylammonium chloride, didecyldimethylammonium chloride, 3-(methoxysilyl)-propyloctadecyldimethylammonium chloride, benzalkonium chloride chloride polyhydric alcohol compounds, alkyltrimethylammonium dibutyrate salts, dicyanamide diethylenetriamine ammonium chloride condensates, and dicyanamide polyalkylenes. It may contain at least one selected from the group consisting of quaternary ammonium salts such as triamine-ammonium chloride polycondensates; phenols such as alkylene bisphenol sodium salts, parachlormetaxylenol, and bis(2,6-di-t-butyl-4-methylphenol) pentaerythrityl diphosphate; amino acids such as N-alkyloyl-L-glutamic acid silver copper; sulfamides such as N,N-dimethyl-N'-(fluorodichloromethylthio)-N"-phenylsulfamide; pyridines such as zinc pyrithione; nitriles such as 2,4,5,6-tetrachloroisophthalonitrile; polymers such as acrylonitrile-acrylic acid copolymer crosslinked products, acrylonitrile copper sulfide complexes, acrylamide-diallylamine hydrochloride copolymers, and methacrylate copolymers; and other substances such as sulfuric acid fullerene.

[0020] The antibacterial and antiviral agent (A) contains, for example, at least one of photocatalyst particles and copper compound particles.

[0021] The copper compound particles can exhibit antibacterial and antiviral effects by the copper ions inhibiting the metabolic functions of fungi and viruses and promoting the decomposition of organic matter. The copper compound particles preferably contain a monovalent copper compound. In this case, the monovalent copper ions can exhibit a higher antibacterial and antiviral effect. It is more preferable that the copper compound contains cuprous oxide (cuprous oxide).

[0022] When the antibacterial and antiviral agent (A) contains photocatalyst particles, a reduction-oxidation reaction occurs on the surface of the photocatalyst particles due to the photocatalytic action of the photocatalyst particles when the coating 3 is irradiated with light, and as a result, the coating 3 can exhibit antibacterial and antiviral action. The photocatalyst particles contain at least one selected from the group consisting of, for example, titanium dioxide, tungsten oxide, strontium titanate, niobium oxide, zinc oxide, and tin oxide. It is preferable that the photocatalyst particles contain titanium dioxide because of its high chemical resistance and easy availability. The titanium dioxide may contain at least one of anatase type titanium dioxide and rutile type titanium dioxide. The photocatalyst particles contain at least one selected from the group consisting of, for example, titanium dioxide, tungsten oxide, strontium titanate, niobium oxide, zinc oxide, and tin oxide.

[0023] It is also preferable that the antibacterial and antiviral agent (A) contains both photocatalyst particles and copper compound particles. In this case, the antibacterial and antiviral action of the copper compound particles can be maintained for a longer period of time. The reason for this is presumed to be as follows. When the coating 3 is irradiated with light, electrons in the valence band of the photocatalyst particles are excited to the conduction band, generating positive holes in the valence band, and the photocatalyst particles are oxidized by these positive holes. Therefore, the photocatalyst particles exhibit antibacterial and antiviral action, but if the copper oxide particles contain divalent copper ions, the divalent copper ions can be reduced by the electrons excited to the conduction band in the photocatalyst particles and changed to monovalent copper ions. Therefore, the antibacterial and antiviral action of the copper oxide particles can be further maintained.

[0024] The average particle size of the antibacterial and antiviral agent (A) is preferably 10 nm or more and 500 nm or less. If the average particle size is 10 nm or more, the antibacterial and antiviral agent (A) can effectively exert its antibacterial and antiviral action. If the average particle size is 500 nm or less, aggregation and precipitation of the particles 5 of the antibacterial and antiviral agent (A) can be suppressed. It is more preferable that the average particle size is 20 nm or more. Furthermore, it is more preferable that the average particle size is 200 nm or less, and even more preferable that the average particle size is 150 nm or less.

[0025] The appearance-adjusting agent (B) is, for example, resin particles, which are made of at least one resin selected from the group consisting of resin particles such as acrylic resin particles, urethane resin particles, polyester resin particles, polyamide resin particles, polystyrene resin particles, polyethylene resin particles, melamine resin particles, urea resin particles, fluororesin particles, polyacrylonitrile resin particles, silk protein (silk powder), and organic matting agents such as polyethylene wax.

[0026] The average particle size of the appearance-adjusting agent (B) is preferably 1 μm or more and 30 μm or less. If the average particle size is 1 μm or more, the particles of the appearance-adjusting agent (B) are less likely to be embedded in the film 3, and the appearance-adjusting agent (B) can impart a good matte appearance to the surface of the film 3. If the average particle size is 30 μm or less, the particles of the appearance-adjusting agent (B) are prevented from settling and agglomerating in the composition (X), and the particles of the appearance-adjusting agent (B) are prevented from falling off from the film 3 due to wear of the film 3, and the durability of the film 3 can be increased. It is more preferable that the average particle size is 1.5 μm or more, and even more preferable that it is 2 μm or more. It is more preferable that the average particle size is 10 μm or less, and even more preferable that it is 5 μm or less.

[0027] As described above, the ratio of the average particle size of the antibacterial and antiviral agent (A) to the average particle size of the appearance-adjusting agent (B) is from 1:2.5 to 1:100. That is, the average particle size of the appearance-adjusting agent (B) is 2.5 to 100 times the average particle size of the antibacterial and antiviral agent (A). Within this range, the coating 3 can exhibit good antibacterial and antiviral properties. When the average particle size of the appearance-adjusting agent (B) is 2.5 times or more the average particle size of the antibacterial and antiviral agent (A), the particles 5 of the antibacterial and antiviral agent (A) are stably held on the surface of the particles 6 of the appearance-adjusting agent (B) in the coating 3, and therefore the particles 5 of the antibacterial and antiviral agent (A) can be present near the surface of the coating 3. For this reason, it is presumed that the action of the antibacterial and antiviral agent (A) is easily exhibited in the coating 3. Furthermore, it is presumed that when the average particle size of the appearance-adjusting agent (B) is 100 times or less than the average particle size of the antibacterial, antiviral agent (A), the particles 5 of the antibacterial, antiviral agent (A) are less likely to sink into the coating 3, and therefore the action of the antibacterial, antiviral agent (A) is more likely to be exerted in the coating 3. It is more preferable that the average particle size of the appearance-adjusting agent (B) is 3 times or more the average particle size of the antibacterial, antiviral agent (A). It is even more preferable that the average particle size of the appearance-adjusting agent (B) is 80 times or less the average particle size of the antibacterial, antiviral agent (A).

[0028] The volume ratio of the antibacterial and antiviral agent (A) to the appearance-adjusting agent (B) is preferably 1:9 to 1:110. In this case, the appearance of the coating 3 and the antibacterial and antiviral properties are easily improved in a well-balanced manner. It is more preferable that the volume of the appearance-adjusting agent (B) is 17 times or more that of the antibacterial and antiviral agent (A), and even more preferable that it is 30 times or more. It is more preferable that the volume of the appearance-adjusting agent (B) is 80 times or less that of the antibacterial and antiviral agent (A), and even more preferable that it is 60 times or less.

[0029] Composition (X) and coating 3 may further contain particles (E) other than the antibacterial and antiviral agent (A) and appearance-adjusting agent (B) to the extent that does not excessively impair the appearance and antibacterial and antiviral properties of coating 3. When composition (X) contains particles (E), the ratio of the volume of particles (E) to the total volume of the antibacterial and antiviral agent (A) and appearance-adjusting agent (B) is preferably 4 times or less, more preferably 2 times or less, and even more preferably 1.5 times or less.

[0030] The binder component (C) is a component for forming the matrix 4 of the coating 3. There are no particular limitations on the binder component (C) as long as it is applicable to forming the coating 3 and ensures the stability and antibacterial and antiviral properties of the coating 3.

[0031] The binder component (C) may contain, for example, a resin that disperses or dissolves in a solvent. In this case, the coating 3 can be produced by adding a solvent to the composition (X), forming the composition (X) into a film, and then volatilizing and removing the solvent.

[0032] The binder component (C) may contain a reactive curing compound. In this case, the coating 3 can be produced by forming the composition (X) into a film and then reacting and curing the reactive curing compound.

[0033] When the binder component (C) contains a reactive curable compound, the binder component (C) may contain an active energy ray curable compound such as a photocurable compound. In this case, the composition (X) can be cured without heating to produce the coating 3 by irradiating the composition (X) with active energy rays. This suppresses oxidation of the antibacterial and antiviral agent (A) due to heating, and the antibacterial and antiviral properties of the antibacterial and antiviral agent (A) in the composition (X) and the coating 3 are less likely to be impaired.

[0034] The binder component (C) may contain at least one selected from the group consisting of, for example, alkyd-based resins, acrylic-based resins, melamine-based resins, urethane-based resins, epoxy-based resins, silicone-based resins, polyester-based resins, polyamic acid-based resins, polyimide-based resins, styrene-maleic acid-based resins, styrene-maleic anhydride-based resins, acrylic acid-based monomers, and acrylate-based monomers.

[0035] When the binder component (C) contains an active energy ray curable compound, the active energy ray curable compound contains, for example, a compound having a radically polymerizable unsaturated bond. The active energy ray curable compound can contain, for example, a polyfunctional (meth)acrylate. More specifically, the active energy ray curable compound can contain at least one selected from the group consisting of pentaerythritols such as pentaerythritol tri(meth)acrylate, dipentaerythritol penta(meth)acrylate, and dipentaerythritol tetra(meth)acrylate, pentaerythritols such as dipentaerythritol tri(meth)acrylate and dipentaerythritol di(meth)acrylate, methylols such as trimethylolpropane di(meth)acrylate, and epoxy acrylates such as bisphenol A diepoxy acrylate. The active energy ray-curable compound preferably contains at least one selected from the group consisting of pentaerythritol tri(meth)acrylate and dipentaerythritol penta(meth)acrylate.

[0036] In addition, "(meth)acrylic" is a generic term that is a higher-level concept of "acrylic" and "methacrylic", and means either "acrylic" or "methacrylic", or both "acrylic" and "methacrylic".

[0037] The binder component (C) is not limited to the above. For example, if the coating 3 can be formed, the binder component (C) may contain an inorganic compound.

[0038] When the binder component (C) contains an active energy ray-curable compound, the composition (X) may further contain a photopolymerization initiator. Examples of the photopolymerization initiator include benzoin compounds having 14 to 18 carbon atoms, such as benzoin, benzoin methyl ether, benzoin ethyl ether, benzoin propyl ether, and benzoin isobutyl ether; acetophenone compounds having 8 to 18 carbon atoms, such as acetophenone, 2,2-diethoxy-2-phenylacetophenone, 2,2-diethoxy-2-phenylacetophenone, and 1,1-dichloroacetophenone; 2-hydroxy-2-methyl-phenylpropan-1-one, diethoxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, and 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one; anthraquinone compounds having 14 to 19 carbon atoms, such as 2-ethylanthraquinone, 2-t-butylanthraquinone, 2-chloroanthraquinone, and 2-amylanthraquinone; the like; ketal compounds having 16 to 17 carbon atoms, such as acetophenone dimethyl ketal and benzyl dimethyl ketal; benzophenone compounds having 13 to 21 carbon atoms, such as benzophenone, 4-benzoyl-4'-methyldiphenyl sulfide and 4,4'-bismethylaminobenzophenone; phosphine oxide compounds having 22 to 28 carbon atoms, such as 2,4,6-trimethylbenzoyldiphenylphosphine oxide and bis-(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentylphosphine oxide; and phosphine oxide compounds, such as bis(2,4,6-trimethylbenzoyl)-phenylphosphine oxide.

[0039] The amount of the photopolymerization initiator is, for example, 0.1 parts by mass or more and 5 parts by mass or less with respect to 100 parts by mass of the active energy ray-curable compound.

[0040] The proportions of the antibacterial and antiviral agent (A), appearance-adjusting agent (B), and binder component (C) in composition (X) can be appropriately adjusted so that the surface of the coating 3 has appropriate unevenness due to the appearance-adjusting agent (B) and so that the ratio of the maximum thickness T1 to the minimum thickness T2 of the coating 3 is appropriately adjusted.

[0041] The proportion of the antibacterial and antiviral agent (A) is, for example, 0.1 to 1 part by mass per 100 parts by mass of the non-volatile components of the composition (X). This proportion is preferably 0.2 or more by mass, and more preferably 0.3 or more by mass. This proportion is more preferably 0.9 or less by mass, and more preferably 0.8 or less by mass.

[0042] The proportion of the appearance-adjusting agent (B) is, for example, 0.5 parts by mass or more and 6 parts by mass or less relative to 100 parts by mass of the non-volatile components of the composition (X). This proportion is more preferably 1 part by mass or more, and even more preferably 1.5 parts by mass or more. This proportion is more preferably 5 parts or less, and even more preferably 4 parts or less.

[0043] The proportion of the binder component (C) is, for example, 5 parts by mass or more and 50 parts by mass or less per 100 parts by mass of the non-volatile components of the composition (X). This proportion is more preferably 6 parts by mass or more, and even more preferably 7 parts by mass or more. This proportion is more preferably 40 parts by mass or less, and even more preferably 20 parts by mass or less.

[0044] The non-volatile components of composition (X) refer to all components in composition (X) excluding the components that volatilize in the process of producing coating 3 from composition (X), i.e., the components that constitute coating 3 out of all components of composition (X).

[0045] In the case where the composition (X) contains a solvent, the solvent contains at least one selected from the group consisting of aromatic hydrocarbons such as toluene and xylene; alcohols such as methanol, ethanol, propanol, 2-propanol, 2-butanol, 1,1,1-trimethylmethanol, ethylene glycol, and propylene glycol; ketones such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; aliphatic hydrocarbons such as hexane and heptane; ethers such as tetrahydrofuran; amide solvents such as N,N-dimethylformamide (DMF) and dimethylacetamide (DMAc); and nitrile solvents such as acetonitrile, propionitrile, and pivalonitrile.

[0046] Composition (X) may contain, as necessary, at least one additive selected from the group consisting of dispersants, antifoaming agents, silane coupling agents, thixotropy-imparting agents, thickeners, antioxidants, and ultraviolet absorbers, etc. The proportion of each additive is preferably 5% by mass or less, and more preferably 2% by mass or less, based on the total amount of composition (X).

[0047] A method for producing the composition (X) will be described. In preparing the composition (X), it is preferable to prepare a dispersion containing the antibacterial and antiviral agent (A) and then mix this dispersion with the appearance-adjusting agent (B) and the binder component (C) to prepare the composition (X).

[0048] In preparing a dispersion liquid containing the antibacterial and antiviral agent (A), for example, the antibacterial and antiviral agent (A) is mixed with a solvent, and then a process of dispersing the antibacterial and antiviral agent (A) is performed using a kneader such as a kneader, a two-roll mill, a three-roll mill, SS5 (trade name, M Technique Co., Ltd.), or Miracle KCK (registered trademark) (trade name, manufactured by Asada Iron Works Co., Ltd.); an ultrasonic disperser; a high-pressure homogenizer such as Microfluidizer (trade name, manufactured by Mizuho Kogyo Co., Ltd.) or Nanovater (registered trademark) (trade name, manufactured by Yoshida Kikai Kogyo Co., Ltd.); Starburst (registered trademark) (trade name, Sugino Machine Co., Ltd.); G-Smasher (trade name, RIX Corporation); a ball mill; a bead mill; a sand mill; a horizontal media mill disperser; or a colloid mill. By adjusting the conditions for the treatment of dispersing the antibacterial, antiviral agent (A), the degree of aggregation of particles 5 of the antibacterial, antiviral agent (A) in the composition (X) can be adjusted, and thus the average particle size of the antibacterial, antiviral agent (A) in the composition (X) can be adjusted.

[0049] As shown in FIG. 1, a coated member 1 according to an embodiment includes a substrate 2 and a coating 3 made of a composition (X) that covers the substrate 2.

[0050] In producing the coating 3, for example, the composition (X) is first applied to the surface of the substrate 2 to produce a coating, and the coating 3 can be produced by curing this coating.

[0051] The method for applying the composition (X) to the substrate 2 is, for example, a spin coating method, a dip coating method, a roll coating method, or a spray coating method, but is not limited to these.

[0052] The coating film is cured by a suitable method according to the composition of the composition (X). For example, the coating film is cured by drying the coating film to volatilize the solvent in the coating film. Furthermore, when the binder component (C) in the composition (X) contains an active energy ray curable compound, the coating film is cured by irradiating the coating film with active energy rays such as ultraviolet rays, electron beams, X-rays, infrared rays, or visible light.

[0053] The coating 3 has an uneven surface, mainly due to particles 6 of the appearance-adjusting agent (B) protruding from the surface of the coating 3.

[0054] The average thickness of the coating 3 is preferably 0.1 μm or more and 5 μm or less. When the thickness is 0.1 μm or more, the coating 3 can have good hardness and durability. When the thickness is 5 μm or less, the antibacterial and antiviral effects of the coating 3 can be more strongly expressed. The average thickness of the coating 3 is more preferably 0.5 μm or more, and even more preferably 0.8 μm or more. The average thickness of the coating 3 is more preferably 3 μm or less, and even more preferably 2 μm or less. The average thickness of the coating 3 is the average value of the thicknesses of 10 convex portions and 10 concave portions that appear in an electron microscope photograph of a cross section of the coating 3 with a length of 50 μm.

[0055] As described above, the ratio of the minimum thickness T2 of the coating 3 to the maximum thickness T1 of the coating 3 is 1:1.1 to 1:4. That is, the maximum thickness T1 of the coating 3 is 1.1 to 4 times the minimum thickness T2 of the coating 3. When the maximum thickness T1 of the coating 3 is 1.1 times or more the minimum thickness T2 of the coating 3, the unevenness of the surface of the coating 3 can impart a good matte appearance to the coated member 1. In addition, the particles 5 of the antibacterial and antiviral agent held by the particles 6 of the appearance adjusting agent (B) tend to be present near the surface of the coating 3, so that the antibacterial and antiviral properties of the antibacterial and antiviral agent (A) tend to be expressed. When the maximum thickness T1 of the coating 3 is 4 times or less the minimum thickness T2 of the coating 3, the particles 5 of the antibacterial and antiviral agent (A) tend to be stably held by the particles 6 of the appearance adjusting agent (B), so that the antibacterial and antiviral properties of the antibacterial and antiviral agent (A) tend to be expressed. The maximum thickness T1 of the coating 3 is more preferably 1.1 times or more, and even more preferably 1.5 times or more, the minimum thickness T2 of the coating 3. The maximum thickness T1 of the coating 3 is more preferably 4 times or less, and even more preferably 2 times or less, the minimum thickness T2 of the coating 3.

[0056] The maximum thickness T1 of the coating 3 is the largest thickness among the thicknesses of the protrusions that appear in an electron microscope photograph of a 50 μm long cross section of the coating 3. The minimum thickness T2 of the coating 3 is the smallest thickness among the thicknesses of the recesses that appear in an electron microscope photograph of a 50 μm long cross section of the coating 3.

[0057] As described above, the base material 2 is preferably a wiring device such as a switch or a socket, but the base material 2 is not limited to a wiring device. In addition to wiring devices such as a switch or a socket, the base material 2 may be a building material such as a ceiling material, a tile, glass, wallpaper, a wall material, a floor or a joinery material; an interior material such as an instrument panel, a seat or a ceiling material of an automobile; a home appliance such as a refrigerator or an air conditioner; a textile product such as clothing or a curtain; industrial equipment; medical equipment; a door, a door handle, a pull handle, a handrail, an interior counter, furniture, a kitchen, a toilet, a bath, a lighting fixture, a touch panel, or the like.

[0058] The material of the substrate 2 may be, for example, but not limited to, metal, ceramics, glass, fiber, nonwoven fabric, film, plastic, rubber, paper, wood, etc. The shape of the substrate 2 may be, for example, a simple shape such as a plate, a sphere, a cylinder, a rod, a prism, or a hollow prism, or a complex shape, but is not limited to these. The substrate 2 may be a porous body.

[0059] The substrate 2 may be a resin film such as a polyethylene terephthalate film. In this case, by overlapping the coating member 1 on another member, the coating member 1 can impart antibacterial and antiviral properties to the other member. In addition, when the substrate 2 is a resin film, it is easy to mass-produce the coating member 1 in a factory or the like, and in this case, it is easy to manage the conditions for producing the coating film 3. Therefore, when imparting antibacterial and antiviral properties to a member, the characteristics of the coating film 3 can be stabilized compared to when the coating film 3 is directly produced on the member. Therefore, the reliability of the coating film 3 is increased. In this case, the substrate 2 in the coating member 1 may simply be overlapped on the other member, or the substrate 2 in the coating member 1 may be bonded to the other member with an adhesive or the like.

[0060] The material of the other member may be, for example, but is not limited to, metal, ceramics, glass, fiber, nonwoven fabric, film, plastic, rubber, paper, wood, etc. The shape of the member may be, for example, a simple shape such as a plate, a sphere, a cylinder, a rod, a prism, or a hollow prism, or a complex shape, but is not limited to these.

[0061] Examples of components include wiring devices such as switches and outlets; building materials such as ceiling materials, tiles, glass, wallpaper, wall materials, floors, or fittings; interior materials such as automobile instrument panels, seats, or ceiling materials; home appliances such as refrigerators or air conditioners; textile products such as clothing or curtains; industrial equipment; medical equipment; doors, door handles, pull handles, handrails, interior counters, furniture, kitchens, toilets, baths, lighting fixtures, or touch panels. EXAMPLES

[0062] Specific examples of the embodiment will be described below.

[0063] 1. Examples and Comparative Examples (1) Example 1 10 parts by mass of silver particles (manufactured by AS ONE, product name Silver Nanoparticle Powder N, average primary particle size 30 nm, specific gravity 5.9), 1 part by mass of a phosphate ester dispersant (manufactured by BYK Japan, product name DISPERBYK-111), and 89 parts by mass of propylene glycol monomethyl ether (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) were mixed, and the mixture was treated for 1 hour at a power of 200 W while cooling and circulating using an ultrasonic dispersion device (manufactured by Hielscher, model number UP200) to obtain a dispersion of silver particles. The particle size distribution of the silver particles in the dispersion was measured using a dynamic scattering method, and the average particle size was calculated from the results to be 120 nm.

[0064] 9 parts by mass of the dispersion of silver particles, 16 parts by mass of ultraviolet-curable resin (polymer-type acrylate, manufactured by DIC Corporation, product name Unidic V-6841, solid content ratio 60% by mass), 1 part by mass of photopolymerization initiator (manufactured by BASF Japan, product name IRGACURE754), 66 parts by mass of solvent (propylene glycol monomethyl ether), and 9 parts by mass of appearance adjuster (crosslinked polymethyl methacrylate particles, manufactured by Sekisui Chemical Co., Ltd., product name Techpolymer MBX-2H, average particle size 3 μm, specific gravity 1.19) were mixed and stirred to obtain a coating composition with a heating residue ratio of 20% by mass. The heating residue is measured in accordance with the Japanese Industrial Standard JIS K5601-1-2 (Paint component test method - Part 1: General rules - Section 2: Heating residue).

[0065] The coating composition was applied to a polyethylene terephthalate film (manufactured by Toyobo Co., Ltd., product name A4360, thickness 100 μm) as the substrate 2 using a bar coater #6 to prepare a coating film, which was then dried by heating at 120°C for 1 minute, and then ultraviolet rays were applied to the coating film using a high-pressure mercury lamp with an integrated light quantity of 300 mJ / cm. 2 The coating film was cured by irradiating it under the conditions described above. In this way, a coating film covering the substrate 2 was produced.

[0066] A cross section of the coating with a length of 50 μm was photographed with an electron microscope, and the thicknesses of 10 convex portions and 10 concave portions shown in the image were measured and the average values ​​of the results were calculated. The maximum thickness of the convex portions was taken as the maximum thickness, and the minimum thickness of the concave portions was taken as the minimum thickness. The results are shown in Table 1.

[0067] (2) Example 2 A dispersion of silver particles was obtained using the same method and conditions as in Example 1, except that cuprous oxide particles (manufactured by Furukawa Chemicals Co., Ltd., product name FRC-N10, average primary particle size 50 nm) were used instead of silver particles. The particle size distribution of the silver particles in the dispersion was measured by a dynamic scattering method, and the average particle size was calculated from the results to be 120 nm.

[0068] A coating covering the substrate was produced in the same manner and under the same conditions as in Example 1, except that this dispersion of silver particles was used.

[0069] As in Example 1, the average thickness, maximum thickness, and minimum thickness of the coating are shown in Table 1.

[0070] (3) Example 3 and Example 4 A coating covering the substrate was produced by the same method and conditions as in Example 2, except that the average particle size of the cuprous oxide particles in the dispersion was adjusted as shown in Table 1 by changing the treatment conditions using the ultrasonic dispersion device. Regarding the treatment conditions using the ultrasonic dispersion device, in Example 3, ultrasonic treatment was performed at an output of 200 W for 15 minutes, and in Example 4, ultrasonic treatment was performed at an output of 100 W for 5 minutes.

[0071] As in Example 1, the average thickness, maximum thickness, and minimum thickness of the coating are shown in Table 1.

[0072] (4) Example 5 A coating covering the substrate was produced using the same method and conditions as in Example 2, except that Sekisui Chemical Co., Ltd.'s Techpolymer SSX101 (crosslinked polymethyl methacrylate particles, average particle size 1.5 μm, specific gravity 1.19) was used as the appearance adjuster.

[0073] As in Example 1, the average thickness, maximum thickness, and minimum thickness of the coating are shown in Table 2.

[0074] (5) Comparative Example 1 A coating covering the substrate was prepared in the same manner and under the same conditions as in Example 1, except that bar coater #3 was used to apply the coating composition.

[0075] As in Example 1, the average thickness, maximum thickness, and minimum thickness of the coating are shown in Table 2.

[0076] (6) Comparative Example 2 A dispersion of silver particles was obtained by the same method and conditions as in Example 2, except that the treatment time using the ultrasonic dispersion device was changed to 30 seconds when preparing the dispersion of silver particles. The particle size distribution of the silver particles in the dispersion was measured by a dynamic scattering method, and the average particle size was calculated from the results to be 1.5 μm.

[0077] As in Example 1, the average thickness, maximum thickness, and minimum thickness of the coating are shown in Table 2.

[0078] (7) Comparative Example 3 A coating covering the substrate was produced using the same method and conditions as in Example 2, except that Sekisui Chemical Co., Ltd.'s Techpolymer MBX-20 (cross-linked polymethyl methacrylate particles, average particle size 20 μm, specific gravity 1.19) was used as the appearance adjuster.

[0079] As in Example 1, the average thickness, maximum thickness, and minimum thickness of the coating are shown in Table 2.

[0080] 2.Evaluation Test (1) Appearance evaluation The gloss of the coating surface was measured using a handheld gloss meter (Horiba, Ltd., product name: Gloss Checker IG-331) at a measurement angle of 60°. If the gloss is 20 or less, the coating surface can be evaluated as being sufficiently matte.

[0081] (2) Antiviral activity evaluation The antiviral activity value of the coating surface against influenza viruses was evaluated according to ISO 21702. An antiviral activity value of 2 or higher can be considered to indicate that a sufficiently high antiviral activity is exhibited.

[0082] [Table 1]

[0083] [Table 2]

[0084] [Aspects] The coated member (1) according to the first aspect includes a substrate (2) and a coating (3) that coats the substrate (2). The coating (3) contains a particulate antibacterial and antiviral agent (A) and a particulate appearance-adjusting agent (B) having a larger average particle size than the antibacterial and antiviral agent (A). The average particle size of the appearance-adjusting agent (B) is 2.5 to 100 times the average particle size of the antibacterial and antiviral agent (A). The maximum thickness (T1) of the coating (3) is 1.1 to 4 times the minimum thickness (T2) of the coating (3).

[0085] According to this embodiment, the covering member (1) can be provided with a matte appearance while also being provided with antibacterial and antiviral properties.

[0086] In a second embodiment, the antibacterial and antiviral agent (A) in the first embodiment contains a copper compound including a monovalent copper compound.

[0087] According to this embodiment, the antibacterial and antiviral properties of the covering member (1) can be further improved.

[0088] In a third embodiment, the antibacterial and antiviral agent (A) in the first or second embodiment contains a copper compound including cuprous oxide.

[0089] According to this embodiment, the antibacterial and antiviral properties of the covering member (1) can be further improved.

[0090] In a fourth aspect, in any one of the first to third aspects, the substrate (2) is a wiring device.

[0091] According to this embodiment, the wiring device can be provided with a matte appearance while also being provided with antibacterial and antiviral properties.

[0092] In a fifth embodiment, in any one of the first to third embodiments, the substrate (2) is a film.

[0093] According to this embodiment, the film can be imparted with antibacterial and antiviral properties while being imparted with a matte appearance, and by overlaying this film on an appropriate member, the member can be imparted with antibacterial and antiviral properties while being imparted with a matte appearance. [Explanation of symbols]

[0094] 1 Covering material 2 Base material 3. Coating 4. Matrix 5 Particles (antibacterial and antiviral particles) 6 Particles (appearance adjuster particles)

Claims

1. A substrate and a coating that covers the substrate, the coating comprises a particulate antibacterial and antiviral agent (A) and a particulate appearance-adjusting agent (B) having an average particle size larger than that of the antibacterial and antiviral agent (A), the ratio of the average particle size of the antibacterial and antiviral agent (A) to the average particle size of the appearance-adjusting agent (B) is from 1:2.5 to 1:100; the ratio of the minimum thickness of the coating to the maximum thickness of the coating is from 1:1.1 to 1:4; Covering material.

2. The antibacterial and antiviral agent (A) contains a copper compound including a monovalent copper compound. The covering member according to claim 1 .

3. The antibacterial and antiviral agent (A) contains a copper compound including cuprous oxide. The covering member according to claim 1 .

4. The substrate is a wiring device. The covering member according to claim 1 .

5. The substrate is a film. The covering member according to claim 1 .

Citation Information

Patent Citations

  • Composition for coating having antibacterial / antiviral and antifouling properties, and coated object

    JP2022093225A